Crossmark

Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China

Crossref DOI link: https://doi.org/10.1186/s13561-025-00656-1

Published Online: 2025-07-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Luwei

Chen, Jiasheng

Lin, Lihui

Huang, Xiaowei
Funding

Funding for this research was provided by:

Xiamen Municipal Bureau of Science and Technology (3502Z20214ZD1233, 3502Z20214ZD1233)

Natural Science Foundation of Fujian Province (2023J011763)
License Information

Text and Data Mining valid from 2025-07-12

Version of Record valid from 2025-07-12
More Information

Article History

Received: 17 March 2025

Accepted: 3 July 2025

First Online: 12 July 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below